Want to see LZAGY full AI Analyst Report?
LZAGY Stock Chart & Stats
$66.71
$0.25(0.41%)
At close: 4:00 PM EST
$66.71
$0.25(0.41%)
Day’s Range― - ―
52-Week Range$59.16 - $73.76
Previous CloseN/A
Volume8.91K
Average Volume (3M)5.62K
Market Cap
$47.75B
Enterprise Value$52.43K
Total Cash (Recent Filing)$719.00M
Total Debt (Recent Filing)$4.54B
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Jul 22, 2026EPS Estimate
1.09Next Dividend Ex-DateN/A
Dividend Yield0.82%
Share Statistics
EPS (TTM)-0.38
Shares Outstanding702,290,200
10 Day Avg. Volume0
30 Day Avg. Volume5,617
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)4.09
Price to Sales (P/S)5.71
P/FCF Ratio-191.57
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.21
Revenue Forecast (FY)$8.90B
Bulls Say, Bears Say
Bulls Say
Upgraded 2026 GuidanceManagement's explicit guidance for double-digit constant-currency revenue growth and entry into a >32% CORE EBITDA corridor demonstrates durable operational leverage and disciplined margin expansion. This implies sustainable profit improvement from higher contract volumes and efficiency gains over the medium term.
Large Contracting PipelineA CHF 10bn+ contracting backlog provides long-term revenue visibility and de-risks growth by locking in multi-year manufacturing and supply agreements. For a CDMO, this converts capacity investments into predictable future cash flows and supports steady utilization over several years.
High‑Margin PlatformsStrong organic growth in high-margin platforms like Advanced Synthesis (margins ~42%) demonstrates portfolio quality and pricing power. High-margin businesses anchor overall profitability, improving resilience to top-line volatility and enabling reinvestment into specialized capacity.
Bears Say
Weak Cash ConversionPersistently negative free cash flow and low operating cash conversion versus reported earnings constrain financial flexibility. Over the medium term this limits capacity to pay down debt, fund buybacks or increase returns without continued high capex or asset sales, raising funding risk.
CapEx And Working Capital IntensitySustained high capital spending and elevated working capital needs compress free cash flow and elongate payback periods. Large, multi-year growth projects increase execution risk and require reliable contracting to earn returns; failure or delays could dilute returns and postpone cash generation.
Operational Risk In Specialized ModalitiesOperational setbacks in Cell & Gene and other specialized modalities risk delaying revenue recognition, harming customer trust, and requiring remediation spend. Given these areas are strategic growth drivers, execution failures can materially slow long-term expansion and raise competitive vulnerability.
Lonza Group News
LZAGY FAQ
What was Lonza Group’s price range in the past 12 months?
Lonza Group lowest stock price was $59.16 and its highest was $73.76 in the past 12 months.
What is Lonza Group’s market cap?
Lonza Group’s market cap is $47.75B.
When is Lonza Group’s upcoming earnings report date?
Lonza Group’s upcoming earnings report date is Jul 22, 2026 which is tomorrow.
How were Lonza Group’s earnings last quarter?
Lonza Group released its earnings results on Jan 28, 2026. The company reported $1.075 earnings per share for the quarter, missing the consensus estimate of $1.191 by -$0.116.
Is Lonza Group overvalued?
According to Wall Street analysts Lonza Group’s price is currently Overvalued.
Does Lonza Group pay dividends?
Lonza Group pays a Annually dividend of $0.571 which represents an annual dividend yield of 0.82%. See more information on Lonza Group dividends here
What is Lonza Group’s EPS estimate?
Lonza Group’s EPS estimate is 1.09.
How many shares outstanding does Lonza Group have?
Lonza Group has 702,290,200 shares outstanding.
What happened to Lonza Group’s price movement after its last earnings report?
Lonza Group reported an EPS of $1.075 in its last earnings report, missing expectations of $1.191. Following the earnings report the stock price went down -2.261%.
Which hedge fund is a major shareholder of Lonza Group?
Currently, no hedge funds are holding shares in LZAGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lonza Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
LZAGY Sentiment 66%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.51%
12-Months-Change
Fundamentals
Return on Equity
0.82%
Trailing 12-Months
Asset Growth
3.12%
Trailing 12-Months
Company Description
Lonza Group
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
Technical Analysis
Ownership Overview
―
Insiders
0.03% Mutual Funds
0.01% Other Institutional Investors
99.96% Public Companies and
Individual Investors